Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers: Pharmacokinetic versus pharmacodynamic approach

European Journal of Clinical Pharmacology

Volumn 50, Issue 5, 1996, Pages 399-405

  Ribeiro, W ^a   Muscara M N ^a   Martins, A R ^b   Moreno Jr , H ^a   Mendes, G B ^a   De Nucci, G ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ACE activity; Bioavailability; Enalapril formulations; Human; Pharmacokinetics

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL MALEATE; EUPRESSIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG FORMULATION; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; VOLUNTEER;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AREA UNDER CURVE; DIPEPTIDES; ENALAPRIL; ENALAPRILAT; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; MALE; PEPTIDYL-DIPEPTIDASE A; RADIOIMMUNOASSAY; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 0029945370     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050130     Document Type: Article

References (23)

1. Todd PA, Goal KI. (1992) Enalapril: A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 43: 346 383
2. Todd PA, Heel RC (1986) Enalapril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31:198 248
3. Ferguson RK, Vlasses PH, Swanson BN, Mojaverian P, Hichens M (1982) Effects of enalapril, a new converting enzyme inhibitor, in hypertension. Clin Pharmacol Ther 32:48 53
4. Sánchez RA, Marcó E, Gilbert HB, Raffaele P, Brito M, Moledo LI (1985) Natriuretic effect and changes in renal haemodynamics induced by enalapril in essential hypertension. Drugs 30 [Suppl 1]:49 58
5. Sánchez RA, Ramírez AJ, Muscará MN, Gilbert HB, Marcó E, Moledo LI (1987) Inhibitory effects of enalapril on serum aldosterone in essential hypertension. Medicina (Bs. As.) 47:256 260
6. Sybertz EJ, Baum T, Ahn HS, Nelson S, Eynon E (1983) Angiotensin converting enzime inhibitor activity of SCH 31846, a new non-sulfhydryl inhibitor. J Cardiovasc Pharmacol 5:643 654
7. Hui SCG, Dai S, Ogle CW (1984) Potentiation of depressor responses to arachidonic acid by angiotensin converting enzyme inhibitors in the rat. Clin Exp Pharmacol Physiol 11:621 625
8. Patchett AA, Harris E, Tristram EW, Wyavratt MJ, Wu MT, Taub D, Peterson ER, Ikeller TJ, Brocke J, Payne LG, Ondeyka DL, Thorsett ED, Greenlee WJ, Lohr NS, Hoffsommer RD, Joshua H, Ruyle WV, Tothrock JW, Aster SD, Maucock AL, Robinson FM, Hirschmann R, Sweet CS, Ulm EH, Gross DM, Vassil TC, Stone CA (1980) A new class of angiotensin-converting enzyme inhibitors. Nature 288:280 283
9. Kelly JG, O'Malley K (1990) Clinical pharmacokinetics of the newer ACE inhibitors, a review. Clin Pharmacokinet 19:177 196
10. MacFadyen RJ, Meredith PA, Elliot HL (1993) Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 25:274 282
11. Donelly R, Meredith PA, Elliot HL, Reid JL (1990) Kineticdynamic relations and individual responses to enalapril. Hypertension 15:301 309
12. Weisser K, Schloos J, Lehmann K, Düsing R, Vetter H, Mutschler E (1991) Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects. Eur J Clin Pharmacol 40:95 99
13. Witte K, Weisser K, Neubeck M, Mutschler E, Lehman K, Hopf R, Lemmer B (1993) Cardiovascular effects, pharmacokinetics and converting enzyme inhibition of enalapril after morning versus evening administration. Clin Pharmacol Ther 54:177 186
14. Dzau VJ (1988) Circulation versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 77 [Suppl 1]: 11 14
15. Falkenhahn M, Gohlke P, Paul M, Stoll M, Unger T (1994) The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects. J Cardiovasc Pharmacol: 24:S6 S13
16. Hichens M, Hand EL, Mulcahy WS (1981) Radioimmunoassay for angiotensin converting enzyme inhibitors. Ligand Q 4:43
17. Cushman DW, Cheung HS (1970) Spectrophotometric assay and properties of the ACE of rabbit lung. Biochem Pharmacol 20:1637 1648
18. Hurst PL, Lovell-Smith CJ (1981) Optimized assay for serum ACE activity. Clin Chem 27:2048 2052
19. Hauschke D, Steinijans VW, Diletti E (1990) A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 28:72-78
20. Food and Drug Administration. Bioavailability and Bioequivalence Requirements. Food and Drug Administration, 4-1-1985 Edition. Federal Register. Part 320, pp 154-173
21. Food and Drug Administration (1993) In vivo bioequivalence guidances. Pharmacopeial Forum 19:6501-6508
22. Larmour I, Jackson B, Cubela R, Johnston CI (1985) Enalapril (MK421) activation in man: importance of liver status. Br J Clin Pharmacol 19:701-704
23. Ohnishi A, Tsuboi Y, Ishizaki T, Kubota K, Ohno T, Yoshida H, Kanezaki A, Tanaka T (1989) Kinetics and dynamics of enalapril in patients with liver cirrhosis. Clin Pharmacol Ther 45:657-665